The malaria drug hydroxychloroquine helped to speed the recovery of a small number of patients who were mildly ill from the coronavirus, doctors in China reported this week.
Cough, fever and pneumonia went away faster, and the disease seemed less likely to turn severe in people who received hydroxychloroquine than in a comparison group not given the drug. The authors of the report said that the medication was promising, but that more research was needed to clarify how it might work in treating coronavirus disease and to determine the best way to use it.
“It’s going to send a ripple of excitement out through the treating community,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University.
The study was small and limited to patients who were mildly or moderately ill, not severe cases. Like many reports about the coronavirus, it was posted at medRxiv, an online server for medical articles, before undergoing peer review by other researchers.
But the findings strongly support earlier studies suggesting a role for the drug, Dr. Schaffner said.
Scientists across the country were still in search of a cure for the coronavirus disease 2019, or COVID-19, on Tuesday, March 31, 2020. Clinical trials were underway as doctors tried to find a way to treat the deadly virus.
Marcus Zervos, infectious disease doctor for Henry Ford Health System, said they had seen success with hydroxychloroquine therapy in a number of COVID-19 patients. He said those given the drug were able to get off a ventilator and out of the hospital faster.
“The goal of therapy is to take patients that have shortness of breath, compromised respiratory status, that have pneumonia, and by treating them with hydroxychloroquine, prevent them from the complication of progression of infection, ending up in an intensive care unit or ending up on a ventilator," Zervos said.
Zervos said it typically took patients hospitalized with COVID-19 between two and four weeks to recover. He said hydroxychloroquine therapy was reducing that recovery time.
Novartis commits to donate up to 130 million doses of hydroxychloroquine to support the global COVID-19 pandemic response
Novartis announced today its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response. Hydroxychloroquine and a related drug, chloroquine, are currently under evaluation in clinical trials for the treatment of COVID-19. Novartis is supporting ongoing clinical trial efforts, and will evaluate needs for additional clinical trials.
When supported for use in COVID-19 infected patients by regulatory authorities, Novartis intends to donate up to 130 million 200 mg doses by the end of May, including its current stock of 50 million 200 mg doses. The company is also exploring further scaling of capacity to increase supply and is committed to working with manufacturers around the world to meet global demand.
Brazilian Hospital started using hydroxychloroquine to treat it's patients, more than 50 already recovered and off ventilators
The Prevent Senior health insurance network last week started the protocol for using hydroxychloroquine associated with azithromycin for patients with Covid-19. In an interview with O Antagonista , executive director Pedro Benedito Batista Júnior revealed that the treatment was successful in more than 50 patients. “Patients who entered therapy and were already intubating showed improvement and some have already been extubated. In the same way, we had more than 50 positive patients who were hospitalized, started treatment, symptoms were controlled and are now at home ”, he says. Batista Júnior considers that the tests are still in the beginning and it is too early to consolidate this treatment protocol. "When I have 1000 patients who are treated in this protocol, then we will compile the results, make a critical analysis of all factors, with all the exams of each person, in order to have a solid scenario."
Hydroxychloroquine is being snapped up by medical systems at more than twice the typical pace as U.S. hospitals seek to build large inventories in anticipation of the medication’s potential use in patients with Covid-19, the respiratory illness caused by the coronavirus.
Dr. William Grace from Lennox Hill Hospital told Laura Ingraham on her show last night that he has been prescribing Hydroxychloroquine to his patients with coronavirus. They have 100 patients and have had zero deaths after the use of Hydroxychloroquine.
Who Am I ?
Just someone trying to highlight the positive news amongst a sea of negativity.